“Cost Effectiveness of Pembrolizumab Vs Chemotherapy As First-Line Treatment for Metastatic NSCLC That Expresses High Levels of PD-L1 in Switzerland”. Swiss Medical Weekly, vol. 149, no. 5152, Dec. 2019, p. w20170, https://doi.org/10.4414/smw.2019.20170.